Younger cancer survivors experience worse survival outcomes following a second primary cancer diagnosis than their older counterparts, according to a recent study.
Michelle Bragazzi, BS, RN
Advanced practice nurses and oncology nurses can benefit from having a better understanding of recently approved immunotherapies and targeted agents, both in how they work and who should be receiving them.
While inflammation is the body’s defense mechanism against pathogens, damaged cells, and chemical irritants, it also has a dark side.
While oncologic emergencies are common among cancer patients, they can often be avoided with close monitoring, early intervention, and ongoing patient education.
Understanding treatment-induced neurotoxicity can be difficult when treating patients with central nervous system (CNS) malignancies.
This session at ONS reviewed treatment options for CLL and the issues associated with bone marrow transplantation in eligible patients.
The topic of obesity and its effect on cancer risk and subsequent treatment was discussed in detail at this year's Oncology Nursing Society annual meeting in Orlando, Florida.
Patients with lung cancer are increasingly receiving targeted therapies that induce complete disease remissions, but they can also develop resistance to these drugs. New efforts are now underway to discover and develop new options for patients experiencing drug resistance.
Oncolytic viruses are receiving more attention these days as a form of cancer treatment, and have shown promise in clinical trials. These viruses are thought not only to cause direct destruction of the tumor cells, but also to stimulate a patient's immune response.
New treatment options for melanoma continue to be developed, especially in the areas of immunotherapies and targeted agents. Oncology nurses need to be knowledgeable about the various therapies being used, indication for use, and the management of adverse events.